Heart failure & cardiomyopathies
Heart Failure ‘The Cancer of the Heart’: The Prognostic Role of the HLM Score
Authors' conclusion
The HLM score has a greater prognostic power compared with the NYHA classification, ACC/AHA stages, and LVEF assessed by transthoracic echocardiography in terms of the composite endpoint of all-cause death and rehospitalization due to HF at 12 months of follow-up.
Study context
- Population
- Consecutive patients admitted for heart failure (HF)completed 12-month follow-up
- Participants
- 1,720 patients
- Exposure
- HLM score vs New York Heart Association (NYHA) class, ACC/AHA stages and left ventricular ejection fraction (LVEF) for prognosis
- Outcome
- Composite of:
- All-cause death
- HF rehospitalization
- Follow-up
- 12 months
Methodological detailsmulticentre, observational, consecutive patients
- Multicentre
- Observational
- Consecutive patients
Main finding
As reported in the abstract
Prediction of composite endpoint
| Group | AUC |
|---|---|
| HLM | 0.645 |
| NYHA | 0.580 |
| ACC/AHA | 0.589 |
| LVEF | 0.572 |
AUC
HLM0.645
NYHA0.580
ACC/AHA0.589
LVEF0.572
- HLM vs LVEF: P = 0.002
- HLM vs ACC/AHA: P = 0.029
- HLM vs NYHA: P = 0.009
Observational data: associations, not effects.
Further findings
Composite endpoint incidence (whole cohort) · 12 months
- Patients with all-cause death or HF rehospitalization
- 520 (30.2%)
Distribution across HLM stages
- HLM-1
- 373 (21.7%)
- HLM-2
- 507 (29.5%)
- HLM-3
- 587 (34.1%)
- HLM-4
- 253 (14.7%)
Original publication
Heart Failure ‘The Cancer of the Heart’: The Prognostic Role of the HLM Score. ESC Heart Fail. Published 27 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →